Correlation Between Halozyme Therapeutics and Monte Rosa

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Monte Rosa at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Monte Rosa into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Halozyme Therapeutics and Monte Rosa Therapeutics, you can compare the effects of market volatilities on Halozyme Therapeutics and Monte Rosa and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Monte Rosa. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Monte Rosa.

Diversification Opportunities for Halozyme Therapeutics and Monte Rosa

0.05
  Correlation Coefficient

Significant diversification

The 3 months correlation between Halozyme and Monte is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Monte Rosa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monte Rosa Therapeutics and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Monte Rosa. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monte Rosa Therapeutics has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Monte Rosa go up and down completely randomly.

Pair Corralation between Halozyme Therapeutics and Monte Rosa

Given the investment horizon of 90 days Halozyme Therapeutics is expected to generate 4.27 times less return on investment than Monte Rosa. But when comparing it to its historical volatility, Halozyme Therapeutics is 3.71 times less risky than Monte Rosa. It trades about 0.05 of its potential returns per unit of risk. Monte Rosa Therapeutics is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  531.00  in Monte Rosa Therapeutics on October 22, 2024 and sell it today you would earn a total of  35.00  from holding Monte Rosa Therapeutics or generate 6.59% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Halozyme Therapeutics  vs.  Monte Rosa Therapeutics

 Performance 
       Timeline  
Halozyme Therapeutics 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Halozyme Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating essential indicators, Halozyme Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2025.
Monte Rosa Therapeutics 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Monte Rosa exhibited solid returns over the last few months and may actually be approaching a breakup point.

Halozyme Therapeutics and Monte Rosa Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Halozyme Therapeutics and Monte Rosa

The main advantage of trading using opposite Halozyme Therapeutics and Monte Rosa positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Monte Rosa can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monte Rosa will offset losses from the drop in Monte Rosa's long position.
The idea behind Halozyme Therapeutics and Monte Rosa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Complementary Tools

Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets